Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation
- PMID: 32556712
- DOI: 10.1007/s00520-020-05572-0
Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation
Abstract
Purpose: The survival rates of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) have improved. However, HSCT can induce significant long-term complications. Therefore, we investigated the late complications and risk factors for quality of life (QOL) post-HSCT.
Methods: We retrospectively analyzed 67 adult survivors over 2 years after HSCT between 2015 and 2018 at Ulsan University Hospital, Ulsan, Korea. The survey data including FACT-BMT, Hospital Anxiety and Depression Scale, and NCCN Distress Thermometer were collected as patient-reported outcomes using a tablet PC during a routine practice of survivorship clinic.
Results: The median age was 46 years. The most common symptom was fatigue (80.6%). Younger age (< 60 years), acute lymphoblastic leukemia (ALL), chronic graft-versus-host disease (GVHD), and immunosuppressant use were significantly associated with worse QOL and depression. Additionally, younger survivors (< 60 years) showed significantly more fatigue and anxiety compared with elderly survivors (≥ 60 years). Female sex was significantly associated with lower physical well-being and higher distress than male sex.
Conclusion: Younger patients (< 60 years), female, ALL, chronic GVHD, and continuous immunosuppressant use were significant risk factors for worse QOL and depression. Hence, creating a more active survivorship care plan after HSCT, specifically for these patients, is required.
Keywords: Allogeneic hematopoietic cell transplantation; FACT-BMT; Fatigue; Hospital Anxiety and Depression Scale; Late complications; Quality of life.
References
-
- Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CF (2015) Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 21:1863–1869. https://doi.org/10.1016/j.bbmt.2015.07.032 - DOI - PubMed - PMC
-
- Martin PJ, Counts GW Jr, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, Flowers MED, Syrjala KL, Hansen JA, Storb RF, Storer BE (2010) Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 28:1011–1016. https://doi.org/10.1200/JCO.2009.25.6693 - DOI - PubMed - PMC
-
- Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socié G (2011) Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29:2230–2239. https://doi.org/10.1200/JCO.2010.33.7212 - DOI - PubMed - PMC
-
- Syrjala KL, Martin PJ, Lee SJ (2012) Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol 30:3746–3751. https://doi.org/10.1200/JCO.2012.42.3038 - DOI - PubMed - PMC
-
- Majhail NS (2017) Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 10:220–227. https://doi.org/10.1016/j.hemonc.2017.05.009 - DOI - PubMed - PMC
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
